Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. more
Time Frame | WINT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -18.42% | 1.76% | -2.5% |
1-Month Return | -27.74% | 0.33% | -3.91% |
3-Month Return | -62.81% | -8.58% | -0.59% |
6-Month Return | -93.16% | -4.26% | 3.45% |
1-Year Return | -97.62% | 1.27% | 22.31% |
3-Year Return | -99.98% | 5.33% | 25% |
5-Year Return | -100% | 38.09% | 77.23% |
10-Year Return | -100% | 102.29% | 188.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 198.00K | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 12.69K | 638.00K | 869.00K | 1.06M | 82.00K | [{"date":"2019-12-31","value":1.2,"profit":true},{"date":"2020-12-31","value":60.13,"profit":true},{"date":"2021-12-31","value":81.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.73,"profit":true}] |
Gross Profit | 185.31K | (638.00K) | (869.00K) | (1.06M) | (82.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-344.28,"profit":false},{"date":"2021-12-31","value":-468.94,"profit":false},{"date":"2022-12-31","value":-572.54,"profit":false},{"date":"2023-12-31","value":-44.25,"profit":false}] |
Gross Margin | 93.59% | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 25.09M | 30.32M | 32.26M | 21.89M | 17.46M | [{"date":"2019-12-31","value":77.78,"profit":true},{"date":"2020-12-31","value":93.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.85,"profit":true},{"date":"2023-12-31","value":54.11,"profit":true}] |
Operating Income | (24.89M) | (30.32M) | (77.28M) | (41.33M) | (17.54M) | [{"date":"2019-12-31","value":-2489300000,"profit":false},{"date":"2020-12-31","value":-3031700000,"profit":false},{"date":"2021-12-31","value":-7728000000,"profit":false},{"date":"2022-12-31","value":-4133300000,"profit":false},{"date":"2023-12-31","value":-1753900000,"profit":false}] |
Total Non-Operating Income/Expense | (2.92M) | (2.25M) | (45.39M) | (19.03M) | (2.48M) | [{"date":"2019-12-31","value":-292400000,"profit":false},{"date":"2020-12-31","value":-225200000,"profit":false},{"date":"2021-12-31","value":-4538600100,"profit":false},{"date":"2022-12-31","value":-1903000000,"profit":false},{"date":"2023-12-31","value":-247700000,"profit":false}] |
Pre-Tax Income | (27.48M) | (32.57M) | (77.62M) | (40.58M) | (20.29M) | [{"date":"2019-12-31","value":-2747500000,"profit":false},{"date":"2020-12-31","value":-3256600000,"profit":false},{"date":"2021-12-31","value":-7762300000,"profit":false},{"date":"2022-12-31","value":-4057500000,"profit":false},{"date":"2023-12-31","value":-2029100000,"profit":false}] |
Income Taxes | 2.39M | (2.29M) | (9.99M) | (1.37M) | (85.89K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-95.77,"profit":false},{"date":"2021-12-31","value":-418.39,"profit":false},{"date":"2022-12-31","value":-57.27,"profit":false},{"date":"2023-12-31","value":-3.6,"profit":false}] |
Income After Taxes | (29.86M) | (30.28M) | (67.64M) | (39.21M) | (20.21M) | [{"date":"2019-12-31","value":-2986200000,"profit":false},{"date":"2020-12-31","value":-3028000000,"profit":false},{"date":"2021-12-31","value":-6763600000,"profit":false},{"date":"2022-12-31","value":-3920800000,"profit":false},{"date":"2023-12-31","value":-2020510500,"profit":false}] |
Income From Continuous Operations | (27.48M) | (32.57M) | (67.64M) | (39.21M) | (20.29M) | [{"date":"2019-12-31","value":-2747500000,"profit":false},{"date":"2020-12-31","value":-3256600000,"profit":false},{"date":"2021-12-31","value":-6763600000,"profit":false},{"date":"2022-12-31","value":-3920800000,"profit":false},{"date":"2023-12-31","value":-2029100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (29.86M) | (30.28M) | (67.64M) | (39.21M) | (20.29M) | [{"date":"2019-12-31","value":-2986200000,"profit":false},{"date":"2020-12-31","value":-3028000000,"profit":false},{"date":"2021-12-31","value":-6763600000,"profit":false},{"date":"2022-12-31","value":-3920800000,"profit":false},{"date":"2023-12-31","value":-2029100000,"profit":false}] |
EPS (Diluted) | - | (82.49) | (66.50) | (43.98) | (8.00) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8249,"profit":false},{"date":"2021-12-31","value":-6650,"profit":false},{"date":"2022-12-31","value":-4398,"profit":false},{"date":"2023-12-31","value":-800,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
WINT | |
---|---|
Cash Ratio | 0.16 |
Current Ratio | 0.27 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
WINT | |
---|---|
ROA (LTM) | -44.76% |
ROE (LTM) | -150.80% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
WINT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.86 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.14 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
WINT | |
---|---|
Trailing PE | NM |
Forward PE | 0.37 |
P/S (TTM) | 660.53 |
P/B | 0.52 |
Price/FCF | NM |
EV/R | 706.08 |
EV/Ebitda | 0.01 |
PEG | NM |
Windtree Therapeutics Inc (WINT) share price today is $0.2529
Yes, Indians can buy shares of Windtree Therapeutics Inc (WINT) on Vested. To buy Windtree Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in WINT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Windtree Therapeutics Inc (WINT) via the Vested app. You can start investing in Windtree Therapeutics Inc (WINT) with a minimum investment of $1.
You can invest in shares of Windtree Therapeutics Inc (WINT) via Vested in three simple steps:
The 52-week high price of Windtree Therapeutics Inc (WINT) is $14.75. The 52-week low price of Windtree Therapeutics Inc (WINT) is $0.26.
The price-to-earnings (P/E) ratio of Windtree Therapeutics Inc (WINT) is
The price-to-book (P/B) ratio of Windtree Therapeutics Inc (WINT) is 0.52
The dividend yield of Windtree Therapeutics Inc (WINT) is 0.00%
The market capitalization of Windtree Therapeutics Inc (WINT) is $2.21M
The stock symbol (or ticker) of Windtree Therapeutics Inc is WINT